Figure 4.

Dolutegravir (DTG) transition is associated with changes in body mass index-for-age z score (BAZ), weight-for age z score (WAZ), and height-for-age z score (HAZ). Predictions were constructed using the following covariate values: male, 14 years old at DTG transition, previously on nevirapine-based antiretroviral therapy, and transitioned to tenofovir disoproxil fumarate/lamivudine/DTG. Predicted BAZ, WAZ, and HAZ and 95% predictive intervals (PIs) were constructed using estimates and the associated standard error of prediction from the fully adjusted models fitted in the whole cohort.